RxDoctor Payments Data

Samantha Cox, DO

Vascular Surgery · Columbia, SCNPI 1699086322

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $8,752 of the $12,106 with a category attached, or 72.3%. Medtronic accounts for 71.1% of it on its own, with 15 other manufacturers making up the rest.

$12,106in general payments, 2019–2025

Across 70 payments — averaging $172.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$9K
  • Silk Road Medical, Inc.$1K
  • W. L. Gore & Associates, Inc.$548
  • Alphatec Spine, Inc$420
  • Bard Peripheral Vascular, Inc.$266
  • KCI USA, Inc.$256
  • plus $889 from 10 others

What the payments were for

  • Travel & lodging$8,75272%
  • Food & beverage$3,35428%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,106 in reported general payments places this provider in the 65th percentile of 99 vascular surgery providers in South Carolina.

See all vascular surgery providers in South Carolina

Medicare billing

Part B allowed, 2024
$103,303
Medicare patients
204
Services billed
571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban36$34,657
XareltoRivaroxaban22$23,715
ClopidogrelClopidogrel Bisulfate111$1,005
Atorvastatin Calcium30$250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$125$23,71522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 99 vascular surgery providers in South Carolina.

Other vascular surgery in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →